本帖最后由 maicon08 于 2023-4-28 15:12 编辑
" V3 u. A& u, b# H( l9 b) }. D& Q# R- i4 n
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。
0 Y/ _: h! Z9 z3 u) h: ?+ ?5 ]% ]# _* Q1 F& N4 |9 g
https://www.163.com/dy/article/I3BTTPRD053438SI.html
5 g8 D8 b3 u3 h, E( H5 X* t& ]+ Y
" u+ x* ^5 E# S2 ^
% q4 b5 Q" ?2 u' N C6 k在研疗法-免疫治疗9 u- h6 H% \4 ]) @3 {, ~0 {
Developmental Therapeutics—Immunotherapy
+ u3 ]: _0 [- w, ^5 u3 r; C0 X ; b, {7 \; S3 _" F, `, x( n% f
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 W" S F3 M+ t H4 L# t& r2 m$ c
在研疗法-分子靶向药物和肿瘤生物学/ w" t) a- k6 W6 {; T; [8 y
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 0 g0 F+ B3 A* d2 ~) h5 U" S+ O
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心 1 F) L; D3 |( }9 y1 \' A* {
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
2 @) Y' P. N% O( U3 B
胃肠道肿瘤-结直肠癌和肛门癌
9 ]5 T8 N* `* F7 V/ ?. b Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 4 T8 f. j' z- T/ s1 \
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary " y% r% ^* m0 }" ~2 x
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 " ]% f- |; X9 e7 p/ ~1 w( S7 `
妇科肿瘤 Gynecologic Cancer
% b% j# X, J' i" I1 k& \摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 + D n: [4 `7 |* X
头颈肿瘤
4 R! s! N/ P0 i1 t. T) m* i0 }) M Head and Neck Cancer
" G T* _: p% F h$ H; H摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
; [5 W5 ^- u* Y) f+ n; i6 Y
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 * e5 Q( l5 O2 }/ |3 F
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心
0 U# T3 T% R/ M6 U8 d3 t% ^5 ]; d: Q
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Q8 _# K2 o( I" C3 c' o I
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
w1 [% Z0 \2 W( {* P. f
血液系统恶性肿瘤-浆细胞疾病6 E1 ]) D" e q0 N- Q7 {
Hematologic Malignancies—Plasma Cell Dyscrasia , x6 U. D3 ~7 H, [
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 3 W! K- |* m/ H: `6 _( j- T- R
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤" e/ E9 G1 t/ @5 j$ X
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
3 t" d$ V4 W" |: {5 }4 b4 T摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 $ }/ y) Y, z: y- z' C* ?
肺癌-转移性非小细胞肺癌
( P, R( k; O" K( r. g, j+ h Lung Cancer—Non-Small Cell Metastatic
* G) ], b7 B+ b3 \) M+ N摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院 , t. L6 b7 w8 d+ E4 @/ Y K5 G; |! j3 n
, j, w& i( \' n
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
+ ~) k5 m. F8 x8 B( [# ?% t) L5 z+ e j
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 5 [& C0 c. r/ s& d; g( \
黑色素瘤/皮肤癌* g V4 \; Q a t$ D5 u( ^8 m& K
Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 ; P" t/ h7 K, f% U. C5 M) X
快速摘要报告( M& Z) K0 {% V6 }$ g3 h. b( z
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心 & j8 k) e8 h' u
临床科学研讨会# u& K% \6 v! s8 Z9 N4 F
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院 # j& D- F0 U* G- F0 p
4 {# ~! `3 ^ h | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
